Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Nathaniel Lizak; Alessandra Lugaresi; Raed Alroughani; Jeannette Lechner-Scott; Mark Slee; Eva Havrdova; Dana Horakova; Maria Trojano; Guillermo Izquierdo; Pierre Duquette; Marc Girard; Alexandre Prat; Pierre Grammond; Raymond Hupperts; Francois Grand'Maison; Patrizia Sola; Eugenio Pucci; Roberto Bergamaschi; Celia Oreja-Guevara; Vincent Van Pesch; Cristina Ramo; Daniele Spitaleri; Gerardo Iuliano; Cavit Boz; Franco Granella; Javier Olascoaga; Freek Verheul; Csilla Rozsa; Edgardo Cristiano; Shlomo Flechter; Suzanne Hodgkinson; Maria Pia Amato; Norma Deri; Vilija Jokubaitis; Tim Spelman; Helmut Butzkueven; Tomas Kalincik

Journal article

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Nathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, Jeannette Lechner-Scott, Mark Slee, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Alexandre Prat, Pierre Grammond, Raymond Hupperts, Francois Grand'Maison, Patrizia Sola, Eugenio Pucci, Roberto Bergamaschi, Celia Oreja-Guevara, Vincent Van Pesch Show all

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | BMJ PUBLISHING GROUP | Published : 2017

DOI: 10.1136/jnnp-2016-313976

Download PDF

Abstract

OBJECTIVE: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple sclerosis (MS), and their modifiability with immunomodulatory therapy. METHODS: The epochs between Expanded Disability Status Scale (EDSS) steps 3-6, 4-6 and 6-6.5 were analysed. Patients with relapse-onset MS and having reached 6-month confirmed baseline EDSS step (3/4/6) were identified in MSBase, a global observational MS cohort study. We used multivariable survival models to examine the impact of disease-modifying therapy, clinical and demographic factors on progression to the outcome EDSS step (6/6.5). Sensitivity analyses with varying outcome definitions and inc..

View full abstract

University of Melbourne Researchers

Timothy Spelman Author Surgery - St Vincent's Hospital

Helmut Butzkueven Author Medicine - Royal Melbourne Hospital

Tomas Kalincik Author Medicine - Royal Melbourne Hospital

Related Projects (3)

Is MS treatment effective long-term?

Multiple Sclerosis is an illness affecting more than 20,000 Australians, and causes significant disability and social disruption in most suf..

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This study was financially supported by National Health and Medical Research Council (practitioner fellowship 1080518, project grants 1083539 and 1032484 and centre for research excellence 1001216), and University of Melbourne Research Fellowship. The MSBase Foundation is a not-for-profit organisation that receives support from Merck, Biogen, Novartis, Bayer-Schering and Sanofi. The study was conducted separately and apart from the guidance of the sponsors.